Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated November 28, 2025, reports a transaction in the company's own shares. The filing covers share repurchase activities executed on November 27, 2025, as part of an existing buyback programme.
Key Financial Metrics and Transaction Details
The filing details a specific block of share repurchases rather than full-period financial results (revenue, profit, or cash flow are not reported in this document).
- Date of Purchase: November 27, 2025
- Aggregate Shares Purchased: 245,000 ordinary shares
- Price Range: Lowest 1,795.50p; Highest 1,812.00p
- Volume-Weighted Average Price (VWAP): 1,804.14p
- Broker: BNP Paribas SA
- Trading Venues: London Stock Exchange (XLON), CHIX, and BATE
Material Changes and Programme Status
The purchase was effected pursuant to a non-discretionary agreement announced on September 30, 2025. Since the commencement of this agreement on September 30, 2025, the Company has purchased a total of 10,893,733 ordinary shares.
Following the November 27 transaction:
- Treasury Shares Held: 236,358,577
- Ordinary Shares in Issue (excluding Treasury): 4,079,073,350
- Total Voting Rights: 4,079,073,350
- Treasury Share Voting Percentage: 5.79% (in accordance with DTR 5.5.1R)
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties, referencing the "Risk Factors" section in GSK's 2024 Annual Report on Form 20-F and Q3 2025 Results.
Investor Verification Checklist
- Verify the total number of shares purchased under the non-discretionary agreement since September 30, 2025 (10,893,733).
- Confirm the updated treasury share count (236,358,577) and its impact on the voting rights denominator (5.79%).
- Review the specific trading venues (XLON, CHIX, BATE) to ensure compliance with market rules.
- Check the volume-weighted average price (1,804.14p) against the prevailing market price on November 27, 2025.